With Sputnik V receiving the green signal today, India is almost set to have 3 COVID-19 vaccines. The expert panel reviewing Dr. Reddy’s Laboratories (DRL’s) application for approval to the Russian vaccine candidates, has recommended that approval should be given to this human adenovirus (flu virus)-based vaccine. However, the final decision is yet to be taken by the Drugs Controller General of India (DCGI).
The Russian vaccine has been registered in 59 countries globally with a total population of over 1.5 billion people. Reports have suggested that the efficacy of Sputnik V is 91.6 percent. If it gets the nod from DCGI as well, then the vaccine will be manufactured in India by several companies including Hetero, Gland Pharma, Stelis Pharma, and Virchow Group.
A total production capacity of over 900 mn has been decided. Out of this 250 mn doses would be for India, while the remaining will be exported by the Russian Direct Investment Fund (RDIF). Currently, India has two vaccines namely Covishield by Serum Institute and Covaxin by Bharat Biotech.